The study drug doses should be calculated taking the body surface area into consideration. Docetaxel 30 mg/m2 will be administered on days 1 and 8 every 3 weeks. Docetaxel will be diluted in 250 ml 0.9% saline or 5% dextrose to produce a final solution with concentration of 0.3-0.74 mg/ml. It will be administered as an infusion over 60 min on each infusion day. Patients will be premedicated with iv dexamethasone 15 mg, antihistamines and a prophylactic antiemetic treatment prior to docetaxel infusion in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Patients experiencing adverse events attributed to irinotecan should have treatment delay as needed and/or may be interrupted or reduced depending on individual tolerability and according to the protocol.